-
公开(公告)号：KR1020150035875A
公开(公告)日：2015-04-07
申请号：KR1020150025886
申请日：2015-02-24
Applicant: 서울대학교산학협력단
IPC: C12N5/0775 , C12N5/0789 , A61K35/28 , A61K35/12
CPC classification number: A61K35/28 , A61K2035/124 , C12N5/0634 , C12N5/0647 , C12N2501/14 , C12N2501/22 , C12N2506/11 , C12N5/0662
Abstract: 본원은 EPO 또는 APS-프라이밍을통해혈관생성능이향상된말초혈액줄기세포의제조방법및 그용도를개시한다. 본원의방법에따라제조된세포는혈관생성을유도하여, 혈관생성의촉진이필요한다양한질환예를들면근육, 뇌, 심장, 신장, 또는대장에서발생한허혈성질환, 예를들면허혈로인한조직손상, 뇌경색, 뇌졸중, 재관류손상, 심근경색, 울혈성심장기능상실, 말초혈관폐색증, 심장비후, 저심장수축증, 저심장이완증, 부적응성심장비대, 수축기심부전, 이완기심부전, 고혈압성심부전, 동맥및 승포판질환, 폐동맥판질환심혈관, 또는허혈성장심혈관재생또는회복에유용하게사용될수 있다.
Abstract translation: 公开了一种通过EPO或APS引发具有增强的血管发生能力及其用途的外周血干细胞的制备方法。 根据本发明产生的细胞诱导血管生成，并且可以有利地用于治疗需要促进血管生成的各种疾病，例如肌肉，脑，心脏，肾脏或大肠中的缺血; 例如缺血 - 触发的组织损伤，脑梗塞，中风，再灌注损伤，心肌梗死，充血性心力衰竭，周围血管阻塞，心脏肥大，收缩期，舒张期，失调的心律失常，收缩期心力衰竭，舒张性心力衰竭，高血压心力衰竭 ，动脉和二尖瓣疾病，肺部疾病，心血管疾病或缺血性心血管疾病。
-
公开(公告)号：KR1020140021154A
公开(公告)日：2014-02-20
申请号：KR1020120086957
申请日：2012-08-08
Applicant: 서울대학교산학협력단
IPC: A61K35/14 , A61K35/15 , C12N5/0786
CPC classification number: A61K35/14 , A61K35/15 , C12N5/0645 , C12N2513/00
Abstract: The present invention provides a pharmaceutical composition for treating ischemic diseases containing human blood derived hematosphere. Specifically the present invention induces vascular smooth muscle cells and vascular endothelial cells through effective three-dimensional culture using mononuclear cells of blood, and ultimately can be applied for the development of a new cell treatment agent for treating the ischemic diseases through effective angiogenesis.
Abstract translation: 本发明提供了一种用于治疗含有人血源性血球的缺血性疾病的药物组合物。 具体地说，本发明通过使用血液的单核细胞的有效的三维培养来诱导血管平滑肌细胞和血管内皮细胞，最终可用于开发新的细胞治疗剂，以通过有效的血管生成治疗缺血性疾病。
-
公开(公告)号：KR1020140021153A
公开(公告)日：2014-02-20
申请号：KR1020120086956
申请日：2012-08-08
Applicant: 서울대학교산학협력단
Abstract: The present invention relates to a technology in which only trace amounts of adult stem cells and progenitor cells present in the blood are effectively cultured and proliferated by using blood mononuclear cells, thereby differentiating inflammatory mononuclear cells into anti-inflammatory mononuclear cells and efficiently securing masses of anti-inflammatory Type 2 helper lymphocytes and regulatory lymphocytes, and a method for treating immune-related diseases using the technology. The anti-inflammatory mononuclear cells, Type 2 helper lymphocytes, and regulatory lymphocytes according to the present invention are immune cells derived from patients, and thus can greatly contribute to the development of cell therapeutic agents for autoimmune diseases.
Abstract translation: 本发明涉及通过使用血液单核细胞有效地培养和增殖存在于血液中的微量成体干细胞和祖细胞的技术，从而将炎症性单核细胞分化成抗炎单核细胞，有效地确保 抗炎2型辅助淋巴细胞和调节性淋巴细胞，以及使用该技术治疗免疫相关疾病的方法。 根据本发明的抗炎单核细胞，2型辅助淋巴细胞和调节性淋巴细胞是来自患者的免疫细胞，因此可大大有助于自身免疫性疾病的细胞治疗剂的发展。
-
公开(公告)号：KR1020130085383A
公开(公告)日：2013-07-29
申请号：KR1020130005902
申请日：2013-01-18
Applicant: 서울대학교산학협력단
Abstract: PURPOSE: A pharmaceutical composition for treatment of metabolic diseases including a blood-born hemosphere (BBHS) is provided to be able to be used as medicine for metabolic diseases by inducing differentiation of BBHS to an insulin-secreting cell. CONSTITUTION: A pharmaceutical composition for treatment of metabolic diseases includes BBHS. The BBHS is formed by isolating monocytic cells from human blood and performing the three dimensional aggregation cultivation. The BBHS is induced to an insulin-secreting cell. The metabolic diseases are selected from a group consisting of diabetes, hyperlipidemia, and obesity. A method of curing metabolic diseases administers the pharmaceutically effective dose of the pharmaceutical composition to an individual.
Abstract translation: 目的：提供一种用于治疗包括血液生成气体（BBHS）在内的代谢疾病的药物组合物，通过诱导BBHS分泌到胰岛素分泌细胞，能够用作代谢疾病的药物。 构成：用于治疗代谢疾病的药物组合物包括BBHS。 BBHS通过从人血液中分离单核细胞并进行三维聚集培养而形成。 BBHS被诱导到胰岛素分泌细胞。 代谢疾病选自糖尿病，高脂血症和肥胖症。 治疗代谢疾病的方法将药物组合物的药学有效剂量给予个体。
-
-
-
Search Results
24
records
(took 0.019 seconds)
